ERBB2 and breast carcinoma: When FASN activity was suppressed by either C75 and si-FASN or lapatinib through the downregulation of HER2-induced FASN phosphorylation, cell invasion was significantly inhibited in HER2-overexpressing SKBR3 and BT474 breast cancer cells.